Pagine dedicate alla Neurologia per l'aggiornamento dei Colleghi e per informazioni sulle nuove terapie e descrizioni di patologie rivolte in modo comprensibile ai pazienti

                                                                                          Dott. Carlo Sebastiano Tadeo
                                                                                                Specialista Neurologia

Avonex per la MS secondariamente progressiva

 

                           Iscrivetevi alle Newsletter                   

                                             Newsletter  

 

 

 Novità dai principali congressi e pubblicazioni scientifiche 

Journals neurology

Per prenotare una visita neurologica

Servizio Traduzione

Medline

Congressi e convegni

Malattie neurologiche

Ictus
Sclerosi Multipla
Alzheimer
Parkinson
Neuropatie ereditarie
Cefalee

 

 

Pubblicità e links utili

 

We subscribe to the HONcode principles of the HON Foundation. Click to verify. We subscribe to the HONcode principles. Verify here.

 

 

www.ilneurologo.com - Candidato al Premio Web Italia 2003

AAN: Avonex (Interferon Beta-1a) Slows Disability Progression In Secondary Progressive Multiple Sclerosis


By Jill Stein

Riassunto

Nuove evidenze indicano che l'Avonex (interferon beta-1a) è un efficace trattamento per la sclerosi multipla verso forma secondaria progressiva.
L'Avonex è stato approvato per il trattamento della forma relapsing remitting.
Nell'ultimo meeting dell'Accademia Americana di Neurologia sono stati presentati dei dati di uno studio in fase 3 che dimostrano che pazienti con la forma secondariamente progressiva di sclerosi multipla trattati con Avonex avevano una riduzione della progressione della disabilità del 40% comparati con i pazienti che ricevevano placebo. 426 pazienti inclusi nel trial

 

PHILADELPHIA, PA -- May 9, 2001-- New findings indicate that Avonex (interferon beta-1a) is an effective treatment for secondary progressive multiple sclerosis (MS).

The Food and Drug Administration (FDA) approved Avonex for the treatment of relapsing remitting MS.

The data, from a phase III study reported at the 53rd Annual Meeting of the American Academy of Neurology (AAN), showed that patients with secondary progressive MS who were treated with Avonex had a 40 percent decrease in the progression of disability compared to patients who received a placebo.

"Our results are important because they demonstrate that Avonex also benefits patients at later stages of the disease," said Dr. Jeffrey A. Cohen, with the Cleveland Clinic Foundation in Cleveland Clinic.

Currently, none of the FDA approved drugs for the treatment of relapsing remitting MS has been approved for the treatment of the secondary progressive form of the disease. The present study tested the efficacy of Avonex for the treatment of the more progressive form of the disease.

The trial included 426 patients with clinically definite MS, a secondary progressive course with or without recent relapses, and a baseline Expanded Disability Status Scale (EDSS) score of 3.5-6.5 inclusive.

Subjects were randomized to treatment with Avonex 60 µg or placebo by weekly intramuscular injection.

The primary disease end point was disease progression as measured by the MS Functional Composite Score (MSFC), a measurement of ambulation, arm movement and cognitive function.

In addition to a decrease in the median disability progression favoring Avonex, Avonex-treated patients had a 33 percent decrease in the disease relapse rate.

No benefit was seen on clinical measures driven by ambulation.

Avonex-treated patients also had improvement in eight of 11 Quality of Life Inventory subscales and experienced a reduction in new or enlarging T2 hyper-intense cranial magnetic resonance imaging (MRI) lesions and gadolinium enhancements at months 12 and 24.

The International Multiple Sclerosis Secondary Progressive Avonex Clinical Trial (IMPACT) was conducted at 42 centers in Europe and North America.

 

Related Link: Avonex (interferon beta-1a).


Per ulteriori informazioni, contattare:

Il Neurologo con voi
Via Copernico 59/a Milano 20125
Tel: 03332699103
Posta elettronica: tadeo@ilneurologo.com

            

Spazio pubblicitario libero

 

Inviare a tadeo@ilneurologo.com un messaggio di posta elettronica contenente domande o commenti su questo sito Web.
Aggiornato il: 18 November 2001